SG11202013088YA - Prophylactic or therapeutic agent for spinal muscular atrophy - Google Patents
Prophylactic or therapeutic agent for spinal muscular atrophyInfo
- Publication number
- SG11202013088YA SG11202013088YA SG11202013088YA SG11202013088YA SG11202013088YA SG 11202013088Y A SG11202013088Y A SG 11202013088YA SG 11202013088Y A SG11202013088Y A SG 11202013088YA SG 11202013088Y A SG11202013088Y A SG 11202013088YA SG 11202013088Y A SG11202013088Y A SG 11202013088YA
- Authority
- SG
- Singapore
- Prior art keywords
- prophylactic
- therapeutic agent
- muscular atrophy
- spinal muscular
- spinal
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 230000000069 prophylactic effect Effects 0.000 title 1
- 208000002320 spinal muscular atrophy Diseases 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C8/00—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools
- A61C8/0093—Features of implants not otherwise provided for
- A61C8/0096—Implants for use in orthodontic treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018122551 | 2018-06-27 | ||
| PCT/JP2019/025732 WO2020004594A1 (ja) | 2018-06-27 | 2019-06-27 | 脊髄性筋萎縮症の予防または治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202013088YA true SG11202013088YA (en) | 2021-02-25 |
Family
ID=68986733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202013088YA SG11202013088YA (en) | 2018-06-27 | 2019-06-27 | Prophylactic or therapeutic agent for spinal muscular atrophy |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US12012410B2 (ru) |
| EP (1) | EP3816160A4 (ru) |
| JP (1) | JP7427252B2 (ru) |
| KR (1) | KR102693282B1 (ru) |
| CN (1) | CN112469707B (ru) |
| AU (2) | AU2019293757B2 (ru) |
| BR (1) | BR112020026637A2 (ru) |
| CA (1) | CA3105174A1 (ru) |
| CL (1) | CL2020003386A1 (ru) |
| CO (1) | CO2021000808A2 (ru) |
| CR (1) | CR20210050A (ru) |
| EA (1) | EA202190116A1 (ru) |
| IL (1) | IL279786B1 (ru) |
| JO (1) | JOP20200338A1 (ru) |
| MX (1) | MX2020014116A (ru) |
| NZ (1) | NZ772352A (ru) |
| PE (1) | PE20211585A1 (ru) |
| PH (1) | PH12020552263A1 (ru) |
| SG (1) | SG11202013088YA (ru) |
| UA (1) | UA128696C2 (ru) |
| WO (1) | WO2020004594A1 (ru) |
| ZA (1) | ZA202100556B (ru) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2579747B8 (en) | 2017-08-04 | 2022-10-05 | Skyhawk Therapeutics Inc | Methods and compositions for modulating splicing |
| KR20210024586A (ko) | 2018-06-27 | 2021-03-05 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 치환된 나프티리디논 화합물 |
| CA3102326A1 (en) * | 2018-07-26 | 2020-01-30 | Domain Therapeutics | Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4 |
| CR20220484A (es) * | 2020-02-28 | 2022-12-15 | Remix Therapeutics Inc | Amidas heterocíclicas y su uso para modular el empalme |
| BR112022020337A2 (pt) * | 2020-04-08 | 2022-12-13 | Remix Therapeutics Inc | Compostos e métodos para modulação de splicing |
| EP4132646A1 (en) * | 2020-04-08 | 2023-02-15 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| JP2023532332A (ja) | 2020-07-02 | 2023-07-27 | リミックス セラピューティクス インコーポレイテッド | 核酸のスプライシング及び増殖性疾患の処置のためのモジュレーターとしての２－（インダゾール－５－イル）－６－（ピペリジン－４－イル）－１，７－ナフチリジン誘導体及び関連する化合物 |
| EP4178963A1 (en) | 2020-07-02 | 2023-05-17 | Remix Therapeutics Inc. | 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| CN112028896A (zh) * | 2020-10-14 | 2020-12-04 | 奥锐特药业(天津)有限公司 | 阿卡替尼的新晶型及其制备方法 |
| IL312078A (en) * | 2021-10-13 | 2024-06-01 | Remix Therapeutics Inc | Compounds and Methods for Modulating Nucleic Acid Splicing |
| TW202330552A (zh) * | 2021-10-13 | 2023-08-01 | 美商雷密克斯醫療公司 | 調節剪接之化合物及方法 |
| WO2023133217A1 (en) | 2022-01-05 | 2023-07-13 | Remix Therapeutics Inc. | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| WO2023133225A1 (en) | 2022-01-05 | 2023-07-13 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| WO2023133229A2 (en) | 2022-01-05 | 2023-07-13 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1050750B (it) * | 1975-12-05 | 1981-03-20 | Erba Carlo Spa | Derivati della 3.4 di idro chinazolina |
| US6566367B2 (en) * | 2000-12-12 | 2003-05-20 | Pfizer Inc. | Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines |
| WO2010019243A1 (en) | 2008-08-13 | 2010-02-18 | Ptc Therapeutics, Inc. | Methods for treating viral infections |
| AU2010262862C1 (en) | 2009-06-17 | 2020-04-30 | Biogen Ma Inc. | Compositions and methods for modulation of SMN2 splicing in a subject |
| GEP201706639B (en) | 2009-08-17 | 2017-03-27 | Intellikine Llc | Heterocyclic compounds and uses thereof |
| AU2010305825A1 (en) | 2009-10-13 | 2012-04-19 | Merck Sharp & Dohme B.V. | Condensed azine - derivatives for the treatment of diseases related to the acetylcholine receptor |
| TWI592411B (zh) | 2011-02-23 | 2017-07-21 | 英特爾立秦有限責任公司 | 激酶抑制劑之組合及其用途 |
| US8710064B2 (en) * | 2011-10-20 | 2014-04-29 | China Medical University | 2-aryl-4-quinazolinones and their pharmaceutical compositions |
| EP2776837A4 (en) | 2011-11-11 | 2015-05-20 | Intellikine Llc | COMBINATION OF KINASEINHIBITORS AND THEIR USE |
| WO2013101974A1 (en) | 2011-12-30 | 2013-07-04 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| JP6193888B2 (ja) | 2012-01-26 | 2017-09-06 | ピーティーシー セラピューティクス， インコーポレイテッド | 脊髄性筋萎縮症を治療するための化合物 |
| MX354074B (es) * | 2012-02-10 | 2018-02-12 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
| CN104302181B (zh) | 2012-03-01 | 2017-09-15 | Ptc医疗公司 | 用于治疗脊髓性肌萎缩的化合物 |
| EP2828247B1 (en) | 2012-03-23 | 2019-01-16 | PTC Therapeutics, Inc. | 4h-chromen-4-one derivatives for treating spinal muscular atrophy |
| US9580393B2 (en) | 2012-12-13 | 2017-02-28 | University Of Kansas | 6-substituted quinazolinone inhibitors |
| US20160089371A1 (en) | 2013-03-15 | 2016-03-31 | Intellikine, Llc | Combination of Kinase Inhibitors and Uses Thereof |
| EP2968340A4 (en) * | 2013-03-15 | 2016-08-10 | Intellikine Llc | COMBINING KINASE INHIBITORS AND USES THEREOF |
| CA2913785C (en) | 2013-06-25 | 2021-08-31 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
| WO2015024876A2 (en) | 2013-08-19 | 2015-02-26 | F. Hoffmann-La Roche Ag | Screening method |
| WO2015095446A1 (en) | 2013-12-19 | 2015-06-25 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| WO2015105657A1 (en) | 2013-12-19 | 2015-07-16 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| WO2015095449A1 (en) | 2013-12-19 | 2015-06-25 | Ptc Therapeutics, Inc. | Methods for modulating the amount rna transcripts |
| PT3143025T (pt) | 2014-05-15 | 2019-12-03 | Hoffmann La Roche | Compostos para tratamento da atrofia muscular espinhal |
| EP3160967B1 (en) | 2014-06-25 | 2019-05-08 | F. Hoffmann-La Roche AG | N-(imidazo[1,2-a]pyrazin-6-yl)-benzamide compounds for treating spinal muscular atrophy |
| WO2016184832A1 (en) | 2015-05-20 | 2016-11-24 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
| CN108026046B (zh) | 2015-07-22 | 2021-12-21 | 亚瑞克西斯制药公司 | 取代的喹唑啉化合物及其作为g12c突变体kras、hras和/或nras蛋白质的抑制剂的用途 |
| WO2017015562A1 (en) * | 2015-07-22 | 2017-01-26 | Araxes Pharma Llc | Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins |
| EA036399B1 (ru) | 2015-11-12 | 2020-11-06 | Ф. Хоффманн-Ля Рош Аг | Композиции для лечения спинальной мышечной атрофии |
| WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| JP6868410B2 (ja) | 2017-02-03 | 2021-05-12 | エスアイアイ・プリンテック株式会社 | 液体噴射ヘッドチップ、液体噴射ヘッドおよび液体噴射装置 |
-
2019
- 2019-06-27 WO PCT/JP2019/025732 patent/WO2020004594A1/ja active Application Filing
- 2019-06-27 EA EA202190116A patent/EA202190116A1/ru unknown
- 2019-06-27 US US17/255,843 patent/US12012410B2/en active Active
- 2019-06-27 NZ NZ772352A patent/NZ772352A/en unknown
- 2019-06-27 CN CN201980048524.9A patent/CN112469707B/zh active Active
- 2019-06-27 CA CA3105174A patent/CA3105174A1/en active Pending
- 2019-06-27 PE PE2020002186A patent/PE20211585A1/es unknown
- 2019-06-27 UA UAA202100217A patent/UA128696C2/uk unknown
- 2019-06-27 JP JP2020527663A patent/JP7427252B2/ja active Active
- 2019-06-27 CR CR20210050A patent/CR20210050A/es unknown
- 2019-06-27 MX MX2020014116A patent/MX2020014116A/es unknown
- 2019-06-27 KR KR1020217002751A patent/KR102693282B1/ko active IP Right Grant
- 2019-06-27 BR BR112020026637-0A patent/BR112020026637A2/pt unknown
- 2019-06-27 EP EP19827283.3A patent/EP3816160A4/en active Pending
- 2019-06-27 AU AU2019293757A patent/AU2019293757B2/en active Active
- 2019-06-27 IL IL279786A patent/IL279786B1/en unknown
- 2019-06-27 JO JOP/2020/0338A patent/JOP20200338A1/ar unknown
- 2019-06-27 SG SG11202013088YA patent/SG11202013088YA/en unknown
-
2020
- 2020-12-23 PH PH12020552263A patent/PH12020552263A1/en unknown
- 2020-12-24 CL CL2020003386A patent/CL2020003386A1/es unknown
-
2021
- 2021-01-26 ZA ZA2021/00556A patent/ZA202100556B/en unknown
- 2021-01-26 CO CONC2021/0000808A patent/CO2021000808A2/es unknown
-
2022
- 2022-12-08 AU AU2022283732A patent/AU2022283732A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112469707A (zh) | 2021-03-09 |
| EP3816160A1 (en) | 2021-05-05 |
| EP3816160A4 (en) | 2022-03-16 |
| JP7427252B2 (ja) | 2024-02-05 |
| NZ772352A (en) | 2024-05-31 |
| JOP20200338A1 (ar) | 2020-12-24 |
| IL279786A (en) | 2021-03-01 |
| IL279786B1 (en) | 2024-10-01 |
| BR112020026637A2 (pt) | 2021-03-30 |
| US20220287748A1 (en) | 2022-09-15 |
| AU2022283732A1 (en) | 2023-02-02 |
| MX2020014116A (es) | 2021-06-15 |
| ZA202100556B (en) | 2024-09-25 |
| CA3105174A1 (en) | 2020-01-02 |
| AU2019293757B2 (en) | 2022-09-15 |
| UA128696C2 (uk) | 2024-10-02 |
| CL2020003386A1 (es) | 2021-05-14 |
| CN112469707B (zh) | 2024-06-21 |
| CR20210050A (es) | 2021-06-10 |
| WO2020004594A1 (ja) | 2020-01-02 |
| US12012410B2 (en) | 2024-06-18 |
| CO2021000808A2 (es) | 2021-04-30 |
| JPWO2020004594A1 (ja) | 2021-07-15 |
| AU2019293757A1 (en) | 2021-02-04 |
| EA202190116A1 (ru) | 2021-08-30 |
| PE20211585A1 (es) | 2021-08-18 |
| KR102693282B1 (ko) | 2024-08-12 |
| PH12020552263A1 (en) | 2021-06-28 |
| KR20210025625A (ko) | 2021-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202100556B (en) | Prophylactic or therapeutic agent for spinal muscular atrophy | |
| IL268519A (en) | Useful preparations in the treatment of spinal muscular atrophy | |
| EP3621565A4 (en) | METHODS AND APPARATUS FOR HUMAN ANATOMICAL ORTHESES | |
| EP3606562A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF SPINAL MUSCLE ATROPHY | |
| EP3837374A4 (en) | COMBINATION THERAPY FOR SPINAL MUSCLE ATROPHY | |
| IL262830A (en) | Preparations and methods for the treatment of spinal muscular atrophy | |
| EP3705104A4 (en) | TIBIO-TARSIAN JOINT OF AN ORTHOSIS OR EXOSKELETON | |
| IL261277A (en) | Combination therapies for treatment of spinal muscular atrophy | |
| EP3781214A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SPINAL MUSCLE ATROPHY | |
| IL276180A (en) | Methods for treating spinal muscular atrophy | |
| EP4013387A4 (en) | COMBINATION THERAPY FOR SPINAL MUSCLE ATROPHY | |
| EP3644879C0 (en) | BONE FIXATION DEVICES | |
| EP3666204A4 (en) | BONE FIXATION DEVICE | |
| EP3603600A4 (en) | EXERCISE APPARATUS FOR LOWER HUMAN BODY ENDS | |
| EP3687520A4 (en) | FIXED-DOSE COMBINATION FORMULATIONS FOR THE TREATMENT OF PAIN | |
| IL292825A (en) | Medical devices for contraception | |
| IL291389A (en) | Orthopedic belt | |
| GB2598857B (en) | Spinal therapy apparatus | |
| EP4069162A4 (en) | ORTHOPEDIC DEVICE | |
| GB201820081D0 (en) | Surgical apparatus | |
| GB2602406B (en) | Telemedicine for orthopedic treatment | |
| GB2586916B (en) | Surgical apparatus | |
| EP3272349A4 (en) | Therapeutic and/or prophylactic agent for lewy body diseases | |
| GB2596640B (en) | Spinal therapy apparatus | |
| EP4032488C0 (en) | SURGICAL DEVICE |